Astellas Pharma US, Inc. Reaches Agreement With DOJ

Astellas Pharma US Inc. has agreed to pay $7.3 million to resolve claims that it marketed and promoted Mycamine for pediatric use from 2005 through 2010, in violation of the False Claims Act. During that period, Mycamine was approved to treat serious fungal infections in adults. State Medicaid programs will receive $3.1 million of the settlement monies and the remaining $4.2 million will be paid to the federal government. Zane D. Memeger, U.S. Attorney for the Eastern District of PA stated that “[t]he settlement in this case further demonstrates our commitment to hold responsible any pharmaceutical company that disregards the FDA drug approval process and promotes drugs for uses before they have been deemed safe and effective”.

For more information, please click here.